In 31 advanced gastric cancer patients, the plasma TGF-β levels of the PSK therapy group (n = 17) decreased compared to the no PSK group (n = 14), thereby antagonizing immune evasion and improving patient prognosis (P = 0.019) [56]. Here, TGFB1 is linked to gastric cancer.